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.2012.05.0Abstract Aim/Background: Treatment of DVT with LMWHs has been shown recently to be as
effective as UFH with suggested lower costs. This study was conducted to determine and compare
the cost of in-patient hospital treatment versus outpatient hospital treatment of patients with DVT.
Method: All adult patients with acute proximal DVT referred to the Emergency Department of
King Khalid University Hospital, Riyadh, Saudi Arabia between August 2009 and August 2010
were invited to the study. An economic analysis was performed to compare the cost impact of out-
patients versus hospital treatment.
Results: Sixty-one patients were included in the study, 31 were followed in the outpatient setting
and 30 as the control group (inpatients). There were no signiﬁcant differences in the outcome
between the outpatient and inpatient group; three patients (9.7%) in the outpatient group and four
patients (13.3%) in the inpatient group had recurrent DVT. Mean nursing cost was $55 for the out-
patient group and $215 for the inpatient group, mean laboratory monitoring cost was $638 for out-
patient group and $1511 for the inpatient group. Hospital stay and doctor’s fees amounted to a
mean of $1000 for outpatient treatment and $2387 for inpatient treatment, p< 0.0001. The mean
outpatient cost was signiﬁcantly lower than the inpatient cost ($1750 vs. $4338, p< 0.0001).
Conclusion: Outpatient treatment of patients with DVT using LMWHs is cost-effective with no
signiﬁcant differences in the outcome of patients. OPD treatment of DVT is feasible in Saudi Arabia
provided there is enough logistic support from thrombosis clinics and those involved in DVT care.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1-4672377; fax: +966-1-4672
(F. Algahtani).
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081. Introduction
Population – based studies have shown that the annual incidence
of deep-vein thrombosis (DVT) can be as high as 0.48–1.6 per
1000 persons (Silverstein et al., 1998; Nordstrom et al., 1992).
As a consequence, the management of DVT incurs consider-
able health care costs. Anticoagulant therapy is the cornerstoneier B.V. All rights reserved.
166 F. Algahtani et al.of the management of venous thromboembolism (VTE). In the
past, the standard treatment of DVT was intravenous unfrac-
tionated heparin (UFH), usually administered for 5–7 days
(Hirsh, 1991). However, because the response of patients to
UFH varies, laboratory monitoring of the anticoagulant effect
is needed, generally requiring admission of the patient to hos-
pital (Hirsh, 1991; Hirsh et al., 1976). In addition when treat-
ing DVT with UFH, failure to achieve an adequate therapeutic
PTT level within the ﬁrst 24 h increases the risk of a recurrent
VTE (Hull et al., 1997).
In recent years, clinical studies of DVT treatments with low
molecular weight heparins (LMWHs) administered once- or
twice- daily have shown that LMWHs are at least as effective
and as well tolerated as UFH (Simonneau et al., 1993; Hull
et al., 1992; Lindmarker and Holmstrom, 1994; Fiessinger
and Lopez, 1996; Columbus Investigators and in the treatment
of patients with venous thrombosis, 1997; Merli et al., 2001).
Furthermore, evidence from meta-analyses suggests that
LMWHs may be more effective than UFH for treating DVT
(Leizorovicz et al., 1994; Lensing et al., 1995; Siragusa et al.,
1996). LMWHs also have advantages over UFH such as subcu-
taneous rather than intravenous administration and laboratory
monitoring of patients is not needed (Hull et al., 1992; Walenga
et al., 1991; Prandoni et al., 1992). This allows patients to be
treated in an outpatient setting (at day clinics) which can in-
crease patient’s convenience and lower treatment costs (Van
den Belt et al., 1998; Gould et al., 1999; Belcaro et al., 1999;
Lindmarker and Holmstrom, 1996). Despite this, only around
20% of outpatients diagnosed with DVT receive treatment in
an outpatient setting (Goldhaber and Tapson, 2004).
In Saudi Arabia, the initial management of uncomplicated
DVT is still with UFH in a hospital inpatient set-up because of
under-developed logistic support from thrombosis clinics. This
study was conducted to determine and compare the cost of
inpatient hospital treatment versus outpatient hospital treat-
ment of patients with DVT. Ethical approval was obtained
from the Deanship of Scientiﬁc Research, College of Medicine,
King Saud University, Riyadh, Saudi Arabia (#08–632) dated
14 June 2008.2. Methods
This is a prospective randomized clinical study, in which pa-
tients were randomized to outpatient treatment with LMWH
or inpatient treatment with the conventional UFH for a mini-
mum of 5–7 days. All symptomatic adult patients (aged over
18 years) with acute proximal DVT of the lower limbs referred
to the Emergency Department of King Khalid University Hos-
pital, King SaudUniversity, Riyadh, Saudi Arabia betweenAu-
gust 2009 and August 2010 were invited to the study. Patients
were randomly assigned into two groups: (a) inpatient treatment
group where they will be treated with the standard UFH proto-
col or to the (b) outpatient treatment group where they will re-
ceive LMWH subcutaneously once daily as outpatients. All
patients received Vitamin K antagonist according to warfarin
nomogram. Study treatment with UFH or enoxparin was dis-
continued when the patient had received at least 5–7 days of
treatment and INR had been maintained above 2 for 48 h.
Incremental cost analysis incurred by the institution while
using the outpatient DVT treatment was performed and was
compared to the cost incurred among patients admitted fortreatment. The cost consequences of replacing inpatient care
with outpatient care were assessed only during the ﬁrst 10 days
of treatment, since the treatment will not differ appreciably
thereafter. Only direct medical costs were taken into account
including the number of days of treatment, the number of
nursing visits, US scans, number of physician visits and num-
ber of blood tests requested. The resources used and costs were
direct hospital costs, expressed in US dollars. The cost of treat-
ment of complications, such hemorrhage were excluded from
the evaluation. All calculations were reﬂected in US dollars.
3. Results
During the one-year evaluation period, a total of 103 patients
were seen and invited to join the study, wherein only 61
(59.2%) gave full consent for the study. Of the 61 patients, thery
were randomized into two groups; 31 into the study group who
were followed in the outpatient setting and 30 as the inpatient/
control group.Mean age of both groups were 49.2 ± 16.5 years
for the outpatient group and 48.4 ± 19.8 years for the inpatient
group (p= 0.854). All patients in the outpatient group had
therapy initiated in the emergency department. Three patients
(9.7%) from the outpatient group and 4 patients (13.3%) from
the inpatient group had recurrent DVT.
The mean direct cost (in US dollars) for outpatient treat-
ment of DVT was $1750 (95% CI $1530 – 1969), which was sig-
niﬁcantly lower than the mean direct cost for inpatient
treatment with UFH ($4338, p< 0.0001) (Table 1). Mean
nursing time was 4.2 ± 2.3 days for the outpatient group and
16.4 ± 11.5 days for the inpatient group. This translated to a
mean cost of $55 for the outpatient treatment and $215 for out-
patient treatment, a mean savings of $160 in nursing costs when
patients were treated as outpatients. The mean costs for labora-
tory monitoring including medical imaging procedures, antico-
agulation monitoring and laboratory tests such as complete
blood count, INR, PT, APTT, serum creatinine and antifactor
Xa levels was signiﬁcantly lower in the outpatient treatment
group compared to the inpatient group ($638 vs. $1511,
p< 0.0001). Hospital stay and doctor’s fees amounted to a
mean of $1000 for outpatients versus $2387 for inpatients,
p< 0.0001. Treatment of DVT costs signiﬁcantly more using
unfractionated heparin (mean of $225) compared to an outpa-
tient treatment with LMWH (mean of $57), p< 0.0001.
4. Discussion
This study was conducted to evaluate the effectiveness, safety,
and economic impact of an outpatient treatment program ver-
sus inpatient treatment for patients with a diagnosis of acute
DVT. Our study conﬁrms the results from a growing number
of investigations that have demonstrated considerable cost
savings with outpatient management of DVT. In our analysis,
this study concluded that the two treatment strategies are
equivalent; since treatment outcomes were similar. In fact,
there were no signiﬁcant differences in the development of
recurrent DVT in either those who had UFH to those who
had outpatient treatment with LMWH (9.7% had recurrent
DVT in the outpatient group versus 13.3% from the inpatient
group). This study found an economic advantage for LMWH
over UFH, although some reports suggested that LMWH
and UFH are equivalent. The American College of Chest
Table 1 Cost analysis: comparison between inpatient and
outpatient therapy of patients with DVT.
Study group
(LMWHs) N= 31
Control
group (UFH)
N= 30
Nursing costs, in US $ 55.00 215.00
Laboratory costs, in US $ 638.00 1511.00
Hospital costs incl. doctor’s
fee, in US $
1000.00 2387.00
Medicine cost, in US $ 57.00 225.00
TOTAL COST 1750.00 4338.00
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of LMWHs for outpatient therapy could save approximately
$250 million US dollars annually in the United States
(Leizorovicz et al., 1994). In some other reports, for every pa-
tient with DVT treated as outpatient could save as much as
$6000 compared with an inpatient UFH treatment. In this
study, outpatient therapy with LMWHs saves approximately
$2588 US dollars per patient, signiﬁcantly lower than reports
from other studies (Van den Belt et al., 1998; Gould et al.,
1999; Belcaro et al., 1999; Lindmarker and Holmstrom, 1996).
Although several studies supported the safety and efﬁcacy
of LMWH for outpatient management of DVT, mortality
advantage is still under question, since deaths are not ascribed
to DVT. However, there is recent evidence that comparable re-
sults pertaining to safety and efﬁcacy of LMWHs are achiev-
able (Leizorovicz et al., 1994). Some reports have advocated
strict exclusion criteria when considering outpatient LMWH
therapy for acute DVT especially when it comes to body
weight and presence of cancer (Spyropoulos, 1999). However,
some reports have shown that even cancer patients who were
included in outpatient treatment programs with LMWH
achieve similar clinical outcomes with their inpatient counter-
parts (Tillman et al., 2000). Therefore, a strict exclusion crite-
ria is unnecessary to withhold LMWH therapy in patients who
may beneﬁt from it the most.
Treatment of DVT with LMWH in an outpatient setting is
feasible, therefore, in Saudi Arabia. In Saudi Arabia, while
outpatient treatment of DVT with LMWH follows a standard
protocol of care, there are major concerns about the level of
supervision, compliance and monitoring of patients undergo-
ing outpatient treatment with LMWH. It may not be sufﬁcient
just to rely on the results of several clinical trials that have
advocated the use of LMWH in routine practice. Resources
and supervision in clinical trials dealing with outpatient treat-
ment of DVT are usually greater than those in routine care.
There is an urgent need to provide logistic support among
thrombosis clinics and thrombotic specialists. A multidisciplin-
ary approach involving general practitioners and primary care
physicians, residents and consultants involved in the manage-
ment of DVT to inform and teach patients about the problem,
its management and complications is needed. A joint collabo-
rative effort should also be in-line to continuously monitor and
further investigate problems encountered in the management
of these patients. The successful implementation of an outpa-
tient DVT management should include a carefully designed
protocol not only directed toward initial evaluation and diag-
nosis but more importantly to patients’ education and support
as well. Once a diagnosis of DVT has been conﬁrmed and thepatient is considered eligible for outpatient treatment, the
emergency physician and nurse should provide the basic infor-
mation necessary for patient’s knowledge such as; reasons for
anticoagulation, importance of compliance, the importance of
monitoring and follow-up and the changes in warfarin dosage
and administration. Proper education of the patient on the
possible side effects, potential drug interactions and risks of
anticoagulation is needed. Prior to leaving the institution, pa-
tients should be informed of the schedule of laboratory testing
and warfarin dose adjustments. If possible, daily home nursing
visits could accomplish this goal along with monitoring pa-
tient’s compliance and presence of complications and side ef-
fects. In a primary care set-up, it would be desirable to
involve the family doctor, general practitioner or a primary
health care physician who has a better knowledge of the pa-
tient’s medical history, compliance and social situation. A joint
or shared responsibility can be most appropriately imple-
mented such for anticoagulation, cancer screening and moni-
toring of platelet count after starting outpatient treatment.
Patients should be encouraged to report any complication or
side effect they notice. In order to accomplish these interre-
lated management tasks of DVT home treatment, a collabora-
tive system of care should include social services and home
nursing care in-line with the hospital-based system of care
operating in a seamless coordinated care.Acknowledgments
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